Nogest (Nomegestrol Acetate)

Nogest, a progestin, acts on the hormonal pathway to prevent pregnancy and to manage menopausal symptoms.

• Contraception: provides progestogen‑only oral contraception by suppressing ovulation and stabilizing the endometrium.
• Menopausal symptom relief: alleviates vasomotor symptoms such as hot flashes as part of hormone replacement therapy.
• Endometrial protection: induces a predictable endometrial pattern during hormone replacement therapy, reducing the risk of hyperplasia.

• Nomegestrol acetate is a selective progesterone receptor agonist. By binding to progesterone receptors in the hypothalamus and pituitary, it inhibits the luteinizing hormone surge, thereby suppressing ovulation. In peripheral tissues, it induces secretory changes in the endometrium, providing contraceptive efficacy and supporting endometrial stability during hormone replacement therapy. The compound exhibits high affinity for the PR‑B isoform and shows minimal activity at androgen or estrogen receptors, contributing to its favorable safety profile.

Adverse reactions to Nogest may vary in frequency and severity, and patients should be aware of both common and serious possibilities.

Common Side Effects

• Nausea: mild stomach upset that often resolves spontaneously.
• Headache: transient tension‑type headache.
• Breast tenderness: mild discomfort or swelling of breast tissue.
• Irregular menstrual bleeding: spotting or changes in cycle length.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs, requiring urgent care.
• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Liver dysfunction: elevated liver enzymes, jaundice, or hepatitis.
• Depression or mood disorders: persistent low mood, anxiety, or suicidal thoughts.

Before prescribing Nogest, clinicians should evaluate patient history and monitor for potential risks.

• Assess thrombotic risk: review personal or family history of clotting disorders and consider alternative contraception if risk is high.
• Monitor liver function: obtain baseline liver enzyme levels and repeat testing periodically during treatment.
• Evaluate blood pressure: measure blood pressure before initiating therapy and monitor regularly for hypertension.
• Contraindicated in pregnancy: avoid use in women who are pregnant or may become pregnant; discuss effective backup methods.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat, and discard after the expiration date.

Nogest can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Combined estrogen products: using additional estrogen‑containing drugs may increase thrombotic risk.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma levels of nomegestrol acetate, decreasing efficacy.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise drug concentrations and heighten side‑effect risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): progestins can affect coagulation parameters; monitor INR closely.
• Antidiabetic agents: hormonal changes may affect glucose control; check blood sugar regularly.
• Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency; observe for abnormal uterine bleeding.